Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Abstract Background There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the cost-effectiveness of ICBs in treating LSCC. The aim of this pa...

Full description

Bibliographic Details
Main Authors: Minyu Cheng, Yanfei Shao, Li Li, Menglao Jiang, Zhouye Song
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Cost-effectiveness
Immunotherapy
Non-small cell lung cancer
Nivolumab
Pembrolizumab
Sintilimab
Online Access:https://doi.org/10.1186/s12885-024-12043-w

Internet

https://doi.org/10.1186/s12885-024-12043-w

Similar Items